3HH2 image
Deposition Date 2009-05-14
Release Date 2009-08-04
Last Version Date 2024-11-27
Entry Detail
PDB ID:
3HH2
Title:
Crystal structure of the myostatin:follistatin 288 complex
Biological Source:
Source Organism:
Mus musculus (Taxon ID: 10090)
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.15 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Growth/differentiation factor 8
Gene (Uniprot):Mstn
Chain IDs:A, B
Chain Length:109
Number of Molecules:2
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Follistatin
Gene (Uniprot):FST
Chain IDs:C, D
Chain Length:288
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding
Embo J. 28 2662 2676 (2009)
PMID: 19644449 DOI: 10.1038/emboj.2009.205

Abstact

Myostatin is a member of the transforming growth factor-beta (TGF-beta) family and a strong negative regulator of muscle growth. Here, we present the crystal structure of myostatin in complex with the antagonist follistatin 288 (Fst288). We find that the prehelix region of myostatin very closely resembles that of TGF-beta class members and that this region alone can be swapped into activin A to confer signalling through the non-canonical type I receptor Alk5. Furthermore, the N-terminal domain of Fst288 undergoes conformational rearrangements to bind myostatin and likely acts as a site of specificity for the antagonist. In addition, a unique continuous electropositive surface is created when myostatin binds Fst288, which significantly increases the affinity for heparin. This translates into stronger interactions with the cell surface and enhanced myostatin degradation in the presence of either Fst288 or Fst315. Overall, we have identified several characteristics unique to myostatin that will be paramount to the rational design of myostatin inhibitors that could be used in the treatment of muscle-wasting disorders.

Legend

Protein

Chemical

Disease

Primary Citation of related structures